Company profile
Silo Pharma, Inc.
NASDAQ: SILO · Healthcare · Biotechnology
#1063 of 1,422 Healthcare companies by revenue41st-percentile growth
EA Score
39DFH 42DQ 34GM 49SS 24
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, growth stability · ↓ workforce scale, operating margin
Methodology →Revenue TTM
$54.1k
Rev growth YoY (TTM)
-25.0%
Net income (FY)
-$4.2M
Employees
3
as of 2026-08-23
Market cap
$3.0M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$72.1k$72.1k2025
Net income-$4.2M-$4.2M2025
Operating income-$4.3M-$4.3M2025
Total assets$7.6M$7.6M2025
Liabilities$1.3M$1.3M2025
Equity$6.3M$6.3M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY20
FY23
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Silo Pharma, Inc.’s revenue?
Silo Pharma, Inc. booked $72.1k in FY2025 revenue, growing 0.0% year over year — about the middle of the pack among Healthcare companies we track, at a -5863.5% net margin.
Peers · Healthcare
RegeneRx Biopharmaceuticals, Inc.——Sky Century Investment, Inc.28DAclarion, Inc.36DIMAC Holdings, Inc.——Paranovus Entertainment Technology Ltd.——PAVmed Inc.40DNeighbors
Sarasota →Key facts
CEOEric Weisblum
SectorHealthcare
IndustryBiotechnology
HeadquartersSarasota, FL
ExchangeNASDAQ: SILO
Employees3
IPO date2021-01-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.